|
Isobutyric acid
|
DB02531 |
|
|
Tetrahydrooxazine
|
DB03862 |
|
|
Bromocriptine
|
DB01200 |
[Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.] |
|
N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide
|
DB03860 |
|
|
Chromic nitrate
|
DB14527 |
|
|
Chromic citrate
|
DB14526 |
|
|
Chromium nicotinate
|
DB14529 |
|
|
Chromium gluconate
|
DB14528 |
|
|
Phosphate ion
|
DB14523 |
|
|
Hydroxide ion
|
DB14522 |
|
|
Chromic cation
|
DB14525 |
|
|
Gallium cation
|
DB14524 |
|
|
Silver cation
|
DB14521 |
|
|
Tetraferric tricitrate decahydrate
|
DB14520 |
|
|
3'-O-Acetylthymidine-5'-Diphosphate
|
DB02549 |
|
|
Anastrozole
|
DB01217 |
[Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955]
Anastrozole was first approved for use in the United States in 1995.[L8863]] |
|
Finasteride
|
DB01216 |
[Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.[L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker.
Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by _in situ_ high levels of DHT.[A178159] In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.[A2132]] |
|
Dantrolene
|
DB01219 |
[Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.] |
|
N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
|
DB03878 |
|
|
Guanosine-5'-Diphosphate-Rhamnose
|
DB02547 |
|
